Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

NCT00680485 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infection
Infections, Bacterial

Interventions

DRUG: GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

Sponsor

GlaxoSmithKline